Production (Stage)
Autolus Therapeutics plc
AUTL
$1.54
$0.010.65%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.98M | 29.00K | -- | -- | 10.09M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.98M | 29.00K | -- | -- | 10.09M |
| Cost of Revenue | 44.69M | 138.30M | 1.22M | 36.61M | 30.67M |
| Gross Profit | -35.70M | -138.28M | -1.22M | -36.61M | -20.58M |
| SG&A Expenses | 29.53M | 42.48M | 27.33M | 21.90M | 18.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 74.22M | 75.89M | 67.65M | 58.52M | 48.85M |
| Operating Income | -65.24M | -75.86M | -67.65M | -58.52M | -38.76M |
| Income Before Tax | -67.94M | -26.14M | -82.07M | -58.22M | -52.70M |
| Income Tax Expenses | 2.23M | 1.46M | 22.00K | 51.00K | -8.00K |
| Earnings from Continuing Operations | -70.16M | -27.61M | -82.09M | -58.27M | -52.69M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -70.16M | -27.61M | -82.09M | -58.27M | -52.69M |
| EBIT | -65.24M | -75.86M | -67.65M | -58.52M | -38.76M |
| EBITDA | -62.96M | -73.79M | -65.72M | -56.62M | -36.95M |
| EPS Basic | -0.26 | -0.10 | -0.31 | -0.22 | -0.24 |
| Normalized Basic EPS | -0.16 | -0.06 | -0.19 | -0.14 | -0.15 |
| EPS Diluted | -0.26 | -0.10 | -0.31 | -0.22 | -0.24 |
| Normalized Diluted EPS | -0.16 | -0.06 | -0.19 | -0.14 | -0.15 |
| Average Basic Shares Outstanding | 266.13M | 266.20M | 266.08M | 266.03M | 222.17M |
| Average Diluted Shares Outstanding | 266.13M | 266.20M | 266.08M | 266.03M | 222.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |